Data Sheet (Cat.No.TMPK-00115)

TargetMol

CD79B Protein, Human, Recombinant (His & Avi)

General Information

Synonyms:	Ig-beta;CD79B;IGB;CD79b molecule;Ig-β;B29;IGBAGM6
Protein Construction:	Ala29-Asp159
Species:	Human
Expression Host:	HEK293 Cells
Accession:	P40259-1
Molecular Weight:	18.1 kDa (predicted). Due to glycosylation, the protein migrates to 33-42 kDa based on Tris-Bis PAGE result.

QC Testing

Biological Activity:	Immobilized Human CD79B, His Tag at 0.5μg/ml (100μl/Well). Dose response curve for Anti-CD79B Antibody, hFc Tag with the EC50 of 3.7ng/ml determined by ELISA.
Purity:	> 95% as determined by Tris-Bis PAGE
Endotoxin:	< 1 EU/μg by the LAL method.
Formulation:	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization.

Preparation and Storage

Reconstitution:

Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Shipping:

In general, Lyophilized powders are shipping with blue ice.

Protein Background

CD79B (also known as B29, Ig beta and B cell antigen receptor complex-associated protein beta-chain) is a 36-40 kDa member of the Ig-Superfamily. It is required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from

dephosphorylation.

Reference

Dornan D, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma[J]. Blood, 2009, 114(13):2721-2729.